The race for access: How the FAIR Act could reclaim U.S. biotech leadership

<p>In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.</p><p><b><strong>Host</strong></b></p><p><a href="https://www.linkedin.com/in/jennifersmithparker/" rel="noopener noreferrer nofollow">⁠Jennifer C. Smith-Parker</a>, Director of Insights, BioSpace</p><p><br /></p><p><b><strong>Guests</strong></b></p><p><a href="https://www.linkedin.com/in/maxgbronstein/" rel="noopener noreferrer nofollow">Max Bronstein</a>, CEO, Aviva Strategies</p><p><a href="https://www.linkedin.com/in/teresa-barnes-85a30814/" rel="noopener noreferrer nofollow">Teresa Barnes</a>, Chief Executive Warrior, PF Warriors</p><p><i><em>Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.</em></i></p>